Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Incannex Healthcare Limited Sponsored ADR ( (IXHL) ).
Incannex Healthcare Inc. held its 2025 Annual Meeting of Stockholders on January 15, 2026, via a virtual live audio webcast, with a quorum representing approximately 34.38% of the company’s 347.7 million eligible common shares present or represented by proxy. At the meeting, shareholders elected Dr. George Anastassov and Robert Clark as directors to serve until the 2028 Annual Meeting, and ratified the appointment of Grant Thornton Audit Pty Ltd as the company’s independent registered public accounting firm for the fiscal year ending June 30, 2026, decisions that confirm continuity in board leadership and external audit oversight for the coming period.
The most recent analyst rating on (IXHL) stock is a Hold with a $0.38 price target. To see the full list of analyst forecasts on Incannex Healthcare Limited Sponsored ADR stock, see the IXHL Stock Forecast page.
Spark’s Take on IXHL Stock
According to Spark, TipRanks’ AI Analyst, IXHL is a Neutral.
The score is held down primarily by weak financial performance (large losses and negative free cash flow) and limited valuation support (negative P/E, no dividend). Technicals are broadly neutral with slightly negative MACD and high volatility risk. Offsetting these, corporate events are a relative positive due to Fast Track designation and favorable clinical/program milestones.
To see Spark’s full report on IXHL stock, click here.
More about Incannex Healthcare Limited Sponsored ADR
Average Trading Volume: 18,781,651
Technical Sentiment Signal: Sell
Current Market Cap: $134.6M
Find detailed analytics on IXHL stock on TipRanks’ Stock Analysis page.